Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. - Hellmann, Matthew D; Rizvi, Naiyer A; Goldman, Jonathan W; Gettinger, Scott N; Borghaei, Hossein; Brahmer, Julie R; Ready, Neal E; Gerber, David E; Chow, Laura Q; Juergens, Rosalyn A; Shepherd, Frances A; Laurie, Scott A; et al. (Lancet Oncology, 2017)